文献速递泌尿男性生殖肿瘤

比较口服紫杉烷ModraDoc006/r与静脉多西他赛治疗转移性去势抵抗性前列腺癌的全球II期随机试验

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2024-03-11

这项全球随机II期试验将103例转移性去势抵抗性前列腺癌(mCRPC)患者按1:1随机分组,比较口服ModraDoc006/r与静脉多西他赛的疗效与安全性。主要终点rPFS在两组间无显著差异(p=0.1465),ModraDoc006/r组中位rPFS为9.5个月,静脉多西他赛组为11.1个月。ModraDoc006/r 20-20/200-100 mg剂量组的安全性显著优于静脉多西他赛,作者认为其可能成为mCRPC的口服紫杉烷治疗选择,但需进一步大型随机试验验证。

要点

  • 口服ModraDoc006/r与静脉多西他赛的rPFS无显著差异(p=0.1465)。
  • ModraDoc006/r组中位rPFS 9.5个月,静脉多西他赛组11.1个月。
  • 20-20/200-100 mg剂量组安全性显著优于静脉多西他赛,无血液学不良事件。

核心结论

  • ModraDoc006/r可能成为mCRPC广泛适用、便捷、有效且耐受性更好的口服紫杉烷治疗选择。
  • 作者认为需进一步在大型随机试验中研究ModraDoc006/r。

研究设计与样本

  • 全球随机II期试验,103例mCRPC患者按1:1随机分入两个队列,均接受泼尼松10 mg每日一次。
  • 队列1共49例接受静脉多西他赛75 mg/m2每3周一次。
  • 队列2共52例接受口服ModraDoc006/r,其中21例起始剂量为ModraDoc006 30 mg联合利托那韦200 mg(晨)及ModraDoc006 20 mg联合利托那韦100 mg(晚)(30-20/200-100 mg),每周两次于21天周期的第1、8、15天给药。
  • 为改善耐受性,另31例起始剂量调整为ModraDoc006/r 20-20/200-100 mg。
  • 纳入标准为化疗初治、可伴或不伴阿比特龙和/或恩扎卢胺预处理、器官功能充分、按RECIST v1.1和PCWG3标准可评估疾病。

主要发现

  • 两臂rPFS无显著差异(p=0.1465)。
  • ModraDoc006/r组中位rPFS为9.5个月,静脉多西他赛组为11.1个月(95% CI)。
  • 可测量疾病患者中,ModraDoc006/r组部分缓解率为44.1%,静脉多西他赛组为38.7%。
  • 可评估病例中,ModraDoc006/r组23例(50%)出现PSA下降50%,静脉多西他赛组26例(56.5%)。
  • ModraDoc006/r 20-20/200-100 mg剂量组安全性显著优于静脉多西他赛,胃肠道毒性多为轻度(主要为1级),无血液学不良事件,神经病变和脱发发生率分别为11.5%和25%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需进一步在大型随机试验中研究ModraDoc006/r。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY AIM: ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. METHODS: 103 mCRPC patients, chemotherapy-naïve with/without abiraterone and/or enzalutamide pretreated, with adequate organ function and evaluable disease per RECIST v1.1 and PCWG3 guidelines were randomized 1:1 into two cohorts. In Cohort 1, 49 patients received docetaxel 75 mg/m2 i.v. every 3 weeks (Q3W). In Cohort 2, 52 patients received ModraDoc006/r; 21 patients with a starting dose of ModraDoc006 30 mg with ritonavir 200 mg in the morning and ModraDoc006 20 mg with ritonavir 100 mg in the evening (30-20/200-100 mg) bi-daily-once-weekly (BIDW) on Days 1, 8, and 15 of a 21-day cycle. To alleviate tolerability, the starting dose was amended to ModraDoc006/r 20-20/200-100 mg in another 31 patients. All patients received prednisone 10 mg daily. Primary endpoint was rPFS. RESULTS: There was no significant difference in rPFS between the 2 arms (p = 0.1465). Median rPFS was 9.5 months and 11.1 months (95% CI) for ModraDoc006/r and i.v. docetaxel, respectively. Partial response was noted in 44.1% and 38.7% measurable disease patients, and 50% decline of PSA was seen in 23 (50%) and 26 (56.5%) evaluable cases treated with ModraDoc006/r and i.v. docetaxel, respectively. The safety profile of ModraDoc006/r 20-20/200-100 mg dose was significantly better than i.v. docetaxel, with mild (mostly Grade 1) gastrointestinal toxicities, no hematologic adverse events, and neuropathy and alopecia incidence of 11.5% and 25%, respectively. CONCLUSIONS: ModraDoc006/r potentially represents a widely applicable, convenient, effective, and better tolerated oral taxane therapy option for mCRPC. Further investigation of ModraDoc006/r in a large randomized trial is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vaishampayan UN, Keessen M, Dreicer R, et al. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. Eur J Cancer. 2024. PMID: 38518534. doi:10.1016/j.ejca.2024.114007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。